Drug: Pembrolizumab (Keytruda, Merck)
Status: Approved for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy
Significant Data:
- Based on a multicenter, nonrandomized, open-label, multicohort Phase Ib study of 192 patients with recurrent or metastatic HNSCC
- Patients were enrolled regardless of tumor human papillomavirus (HPV) status (HPV-positive, 33%)
- The data showed an